|Mr. Lars Fruergaard J�rgensen||Pres & CEO||N/A||N/A||51|
|Mr. Jesper Brandgaard||Exec. VP of Biopharma & Legal Affairs||N/A||N/A||54|
|Dr. Mads Krogsgaard Thomsen||Exec. VP & Chief Science Officer||N/A||N/A||57|
|Ms. Liselotte Hyveled||Director||116.58k||N/A||51|
|Mr. Karsten Munk Knudsen||Exec. VP & CFO||N/A||N/A||45|
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S’s ISS Governance QualityScore as of February 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 9; Compensation: 3.